Germany’s Biotechnology Company BioNTech and China’s Shanghai Fosun Pharmaceutical have announced the start of another COVID-19 vaccine trial in China. BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China.
Daily Current Affairs Quiz 2020
Key-Points
The randomized, placebo-controlled, observer-blinded Phase 1 clinical trial in China will enroll 144 healthy subjects to evaluate the safety and immunogenicity of the vaccine as well as to confirm dose selection.
The trial is part of BioNTech’s global development program aimed at supporting a global supply upon regulatory approval.
The study is designed to support the regulatory approval process for the Chinese market and intends to confirm that the safety and immunogenicity profile observed in participants from the German and US trials is comparable to that of Chinese participants.
The ongoing clinical studies conducted in Germany and the United States will continue to support studies in China.